William Blair: 'we continue to view BridgeBio as a core smidcap biotech holding'
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall St tumbles on tech selloff as concerns about hawkish Fed, AI spending mount
- Chip stocks plunge, but bargain-hunters stem losses in other tech names
- Oil drops $1 as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Trump announces nuclear deal with Iran, lifts Hormuz blockade
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Raymond James on BridgeBio Pharma (BBIO): 'We expect continued strong commercial momentum for Attruby'
April 28, 2026 2:00 PM EDTRaymond James analyst Martin Auster reiterated an Outperform rating and $89.00 price target on BridgeBio Pharma (NASDAQ: BBIO).
The analyst comments "Today, Pfizer announced (here) that the company has entered into settlement agreements with several generic drug manufacturers over patent infringement lawsuits relating to Pfizers blockbuster ATTR-CM product, Vyndamax (tafamidis). Here, we summarize key takeaways and contextualize readthrough to BridgeBios lead ATTR-CM asset, Attruby. Vyndamax settlements and June 2031 LoE timeline roughly within Street expectations. Todays settlements extend the effective U.S. patent expiry for Vyndamax to June 1, 2031 (pending other... More
Barclays on BridgeBio Pharma (BBIO): 'We see buying opportunity on weakness, reiterate top idea'
April 28, 2026 12:14 PM EDTBarclays analyst Eliana Merle reiterated an Overweight rating and $157.00 price target on BridgeBio Pharma (NASDAQ: BBIO).
The analyst comments "Our take on BBIO shares from here: While we think many investors had hoped for a later date (~'33+), particularly after yesterday at trial... More
TD Cowen on BridgeBio Pharma (BBIO): 'A key overhang is removed now'
April 28, 2026 11:46 AM EDTTD Cowen analyst Tyler Van Buren reiterated a Buy rating and $95.00 price target on BridgeBio Pharma (NASDAQ: BBIO).
The analyst comments "The PFE taf settlement date of June 2031 (w/ potential for 6 mos of exclusivity) gives BBIO 7.5-8 years to launch... More
